Compare Monolithic Power Systems Inc (MPWR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Recursion Pharmaceuticals Inc — how do they compare? Monolithic Power Systems Inc trades at $1,364.15 (market cap $67.32B), while Recursion Pharmaceuticals Inc trades at $4.23 (market cap $2.14B). The key difference: Monolithic Power Systems Inc is far larger — about 31.5× Recursion Pharmaceuticals Inc's market cap, and Monolithic Power Systems Inc pays a 0.58% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MPWR | RXRX | |
|---|---|---|
Market Cap | $67.32B | $2.14B |
Volume | 826,960 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $1.69K | $6.79 |
52-Week Low | $856.96 | $2.84 |
Typical Hold Time | 25 Days | 22 Days |
Enterprise Value | $65.92B | $1.66B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,425.98, down 3.24% today but maintains strong technical momentum with bullish moving averages and key support at $1,417. The company demonstrates robust fundamentals with 24.5% net margins and consistent earnings beats, while expanding manufacturing capacity through the GlobalFoundries partnership announced September 9, 2026. Analyst sentiment remains overwhelmingly positive with 88% buy ratings and a $1,830 consensus price target representing 28% upside potential.
MPWR presents compelling growth exposure to AI infrastructure demand but carries premium valuation risks. The stock's 83.6 P/E ratio requires sustained high growth execution, while insider selling and competitive pressures warrant monitoring. Current technical positioning near pivot point resistance at $1,427 suggests near-term consolidation before potential breakout toward analyst targets.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
